Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey. The company is dedicated to developing and commercializing products that address unmet medical needs, particularly in the areas of inflammation, oncology, and biodefense. Soligenix operates through two business segments: Specialized BioTherapeutics and Public Health Solutions.
Under the Specialized BioTherapeutics segment, Soligenix focuses on rare disease treatments. Key projects include HyBryte™ (SGX301), a novel photodynamic therapy using synthetic hypericin for cutaneous T-cell lymphoma (CTCL). HyBryte™ has shown promising results in Phase 3 clinical trials and is on track for regulatory approvals in the United States and Europe. Other development programs include SGX302 for psoriasis, SGX942 for oral mucositis in head and neck cancer, and SGX945 for Behçet's disease.
The Public Health Solutions segment emphasizes vaccine development and biodefense. Notable projects include RiVax®, a ricin toxin vaccine candidate, and thermostable vaccine candidates for filoviruses such as Marburg and Ebola. These vaccines are developed using the company's proprietary heat stabilization platform technology, ThermoVax®. Soligenix has also been active in developing CiVax™, a vaccine candidate for COVID-19.
Recent achievements include additional patents for their trivalent filovirus vaccine platform and positive clinical trial results for HyBryte™. Financially, the company reported a net loss for the quarter ended March 31, 2024, but successfully raised $4.75 million through a public offering. Soligenix has also secured significant non-dilutive government funding to support its various development programs.
Partnerships with esteemed institutions like the University of Hawaiʽi at Mānoa and funding from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) further bolster Soligenix's research and development efforts. With a robust pipeline and strategic collaborations, Soligenix aims to deliver significant long-term value to its shareholders and address critical healthcare needs globally.
Soligenix, a late-stage biopharmaceutical company, is urging eligible stockholders to vote 'FOR' a Reverse Stock Split. The company aims to maintain its Nasdaq listing, which is critical for advancing its HyBryte™ Phase 3 trial and other clinical programs, as well as securing institutional support and potential non-dilutive government funding. Eligible stockholders as of April 10, 2024, can vote by contacting Alliance Advisors at 1-833-782-7145. Soligenix emphasizes that even those who have sold their shares after this date are still eligible to vote.
Soligenix announced that Professor Axel Lehrer from the University of Hawaiʽi will present data on their thermostable vaccine technology at the Vaccine Technology IX Conference in Los Cabos, Mexico, from May 19-24, 2024. The technology includes filovirus vaccine candidates SuVax™ and MarVax™. The presentation will cover the optimization of vaccine formulation focused on safety and thermostability. Soligenix's vaccines, developed under their Public Health Solutions segment, use GRAS excipients and lyophilization for stability, protecting against Sudan ebolavirus and Marburg marburgvirus in non-human primate studies. The company has received Orphan Drug Designation for these vaccines.
Soligenix (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, urges stockholders to vote in the Annual Meeting on May 23, 2024. This meeting, to be held virtually at 9:00 AM ET, is important for advancing the company's pipeline, including a Phase 3 study of HyBryte™ for cutaneous T-cell lymphoma (CTCL). Voting is open to stockholders of record as of April 10, 2024, even if shares have been sold since. Voting can be done online, by phone, or by mail until 11:59 PM ET on May 22, 2024.
Soligenix announced positive results from its HyBryte™ compatibility study for treating cutaneous T-cell lymphoma (CTCL), published in JEADV Clinical Practice. The study, HPN-CTCL-02, enrolled 9 patients, revealing a 22% treatment response rate after 8 weeks of HyBryte™ therapy. The results align with the Phase 3 FLASH trial, showing an average improvement of 36.4% in cumulative mCAILS scores. Key metrics included low systemic hypericin levels and no adverse effects on cardiac rhythm, confirming HyBryte™'s safety. The study points to the potential real-world use of HyBryte™ and precedes a confirmatory Phase 3 FLASH2 study.
Soligenix, a biopharmaceutical company, announced recent accomplishments and first quarter 2024 financial results. They completed a public offering with gross proceeds of $4.75 million, received orphan drug designations, and initiated various clinical trials. The company's revenue decreased to $0.1 million, net loss increased to $1.9 million, research and development expenses grew due to upcoming trials, and general and administrative expenses decreased. Cash position was $7.1 million as of March 31, 2024.
Soligenix, Inc. (Nasdaq: SNGX) announced its participation in upcoming conferences like the Aegis Virtual Conference, BioNJ's 14th Annual BioPartnering Conference, and A.G.P./Alliance Global Partners Healthcare Company Showcase. These events provide opportunities for presentations, networking, and one-on-one meetings with key members of Soligenix management. The Company aims to deliver a corporate presentation to investors, institutional funds, and money managers, showcasing its late-stage biopharmaceutical products for rare diseases.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
What does Soligenix, Inc. specialize in?
What are the key projects under Soligenix's Specialized BioTherapeutics segment?
What is ThermoVax®?
What achievements has Soligenix recently made?
Who are some of Soligenix's key partners?
What financial milestones has Soligenix achieved?
What is HyBryte™?
What is CiVax™?
What is RiVax®?
What are Soligenix's key areas of focus in vaccine development?
